Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Transitional Cell 15Neoplasms 14Ovarian Neoplasms 13Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Carcinoma, Merkel Cell 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Melanoma 7Stomach Neoplasms 6Recurrence 5Breast Neoplasms 5Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Lymphoma, Non-Hodgkin 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Urothelial Cancer 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × avelumab × Clear all
NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Pfizer

Phase 2 Terminated
202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡